• Redcare Pharmacy reported a net loss of EUR 6.9 million in H1 2026, widening from the prior-year period; basic EPS was EUR -0.29.
• Revenue rose 19% to EUR 1.7 billion, while gross margin fell 2.1 percentage points to 21.5%.
• Adjusted EBITDA rose 62% to EUR 44 million, lifting the adjusted EBITDA margin to 2.6% from 1.9% a year earlier.
• Active customers climbed by 1.2 million year over year to 14.7 million, with repeat orders steady at 90%.
• Full-year guidance was upgraded in June and reaffirmed, targeting 15%-17% revenue growth and a 2.5%-3.0% adjusted EBITDA margin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redcare Pharmacy NV published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.